Journal of diabetes investigation · 2026
Effects of switching from MiniMed™ 770G to 780G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takagi Eri, Sato Junko, Ayame Tatsuhiro, Fujikawa Shohei, Mori Ryoki, Yasuda Haruna, Ozaki Azusa, Nagashima Haruki, Koshibu Mami, Nishida Yuya, Ikeda Fuki, Watada Hirotaka
Аннотация
AIMS: We sought to compare the MiniMed™ 770G to the 780G insulin pump for glycemic control and quality of life in Japanese adults with T1D over a one-year period.
METHODS: Thirty-six adults with T1D who switched from the MiniMed™ 770G to the 780G system were analyzed over 48 weeks using continuous glucose monitoring data, retrospectively. The percentages of time within the target glucose range (70-180 mg/dL), time above 180 mg/dL, and time below 70 mg/dL were compared before and after switching. Quality of life (QOL) scores were also evaluated in 39 patients using a validated questionnaire, prospectively.
RESULTS: After switching to the MiniMed™ 780G, the time within the target glucose range significantly increased from 71.6 ± 12.4% to 76.1 ± 10.2% (P < 0.01), while the time above 180 mg/dL decreased from 25.2 ± 13.4% to 21.0 ± 11.0% (P < 0.01). The time below 70 mg/dL did not differ significantly overall, but nocturnal hypoglycemia decreased from 4.9% to 2.7% (P = 0.02). Glycated hemoglobin improved from 7.2 ± 0.8% to 7.0 ± 0.7% (P < 0.01). Although the total QOL score did not change significantly, the subscales reflecting anxiety and treatment satisfaction improved significantly.
CONCLUSIONS: Switching from the MiniMed™ 770G to the 780G system in Japanese adults with T1D improved both glycemic control and treatment-related QOL, supporting the clinical usefulness of the 780G in real-world clinical practice. This study provides the first one-year real-world evidence of MiniMed™ 780G use in Japan.
METHODS: Thirty-six adults with T1D who switched from the MiniMed™ 770G to the 780G system were analyzed over 48 weeks using continuous glucose monitoring data, retrospectively. The percentages of time within the target glucose range (70-180 mg/dL), time above 180 mg/dL, and time below 70 mg/dL were compared before and after switching. Quality of life (QOL) scores were also evaluated in 39 patients using a validated questionnaire, prospectively.
RESULTS: After switching to the MiniMed™ 780G, the time within the target glucose range significantly increased from 71.6 ± 12.4% to 76.1 ± 10.2% (P < 0.01), while the time above 180 mg/dL decreased from 25.2 ± 13.4% to 21.0 ± 11.0% (P < 0.01). The time below 70 mg/dL did not differ significantly overall, but nocturnal hypoglycemia decreased from 4.9% to 2.7% (P = 0.02). Glycated hemoglobin improved from 7.2 ± 0.8% to 7.0 ± 0.7% (P < 0.01). Although the total QOL score did not change significantly, the subscales reflecting anxiety and treatment satisfaction improved significantly.
CONCLUSIONS: Switching from the MiniMed™ 770G to the 780G system in Japanese adults with T1D improved both glycemic control and treatment-related QOL, supporting the clinical usefulness of the 780G in real-world clinical practice. This study provides the first one-year real-world evidence of MiniMed™ 780G use in Japan.